Abstract
Microcystins (MCYs) are cyanobacterial heptapeptides known for their high toxicity in eukaryotic cells and for their potential human health hazards. They are potent and specific inhibitors of type 1 and 2A, serine-threonine protein phosphatases (PP1 and PP2A) and as such, interfere with key cellular and metabolic events. Moreover, they induce oxidative stress involving reactive oxygen species (ROS) generation. Their cytoskeletal effects involve both mitotic and differentiated eukaryotic cells. The main objective of the present review is to summarize the most important cytoskeletal effects of MCY on human, animal and plant cells known to date and to give an insight into the cellular and molecular background of these alterations. Disruptions of microtubule (MTs), microfilament (MF) and intermediate filament (IF) organization have all been described, having consequences on cell shape, tissue integrity and functionality and mitotic division. Most of these subcellular changes are closely related to PP1 and PP2A inhibition and involve misfunctioning of cytoskeleton associated proteins. However, several cytoskeletal alterations are likely to be related to the induction of oxidative stress. MCY induced changes in MT, MF and IF assembly may have severe human health consequences. The main target of cyanotoxin in human/ animal cells is liver and cytoskeletal disruption alters structure and functioning of hepatocytes. However, many other cell types undergo alterations similar to those observed in hepatocytes. Both PP1/PP2A inhibition and ROS generation are involved and the activation of mitogen activated protein kinases (MAPKs) seems to play a crucial role in the molecular events leading to cytoskeletal disruption.
Keywords: Intermediate filaments, microcystin, microfilaments, microtubules, oxidative stress, protein phosphatase.
Mini-Reviews in Medicinal Chemistry
Title:The Effects of Microcystins (Cyanobacterial Heptapeptides) on the Eukaryotic Cytoskeletal System
Volume: 16 Issue: 13
Author(s): Csaba Máthé, Dániel Beyer, Márta M-Hamvas and Gábor Vasas
Affiliation:
Keywords: Intermediate filaments, microcystin, microfilaments, microtubules, oxidative stress, protein phosphatase.
Abstract: Microcystins (MCYs) are cyanobacterial heptapeptides known for their high toxicity in eukaryotic cells and for their potential human health hazards. They are potent and specific inhibitors of type 1 and 2A, serine-threonine protein phosphatases (PP1 and PP2A) and as such, interfere with key cellular and metabolic events. Moreover, they induce oxidative stress involving reactive oxygen species (ROS) generation. Their cytoskeletal effects involve both mitotic and differentiated eukaryotic cells. The main objective of the present review is to summarize the most important cytoskeletal effects of MCY on human, animal and plant cells known to date and to give an insight into the cellular and molecular background of these alterations. Disruptions of microtubule (MTs), microfilament (MF) and intermediate filament (IF) organization have all been described, having consequences on cell shape, tissue integrity and functionality and mitotic division. Most of these subcellular changes are closely related to PP1 and PP2A inhibition and involve misfunctioning of cytoskeleton associated proteins. However, several cytoskeletal alterations are likely to be related to the induction of oxidative stress. MCY induced changes in MT, MF and IF assembly may have severe human health consequences. The main target of cyanotoxin in human/ animal cells is liver and cytoskeletal disruption alters structure and functioning of hepatocytes. However, many other cell types undergo alterations similar to those observed in hepatocytes. Both PP1/PP2A inhibition and ROS generation are involved and the activation of mitogen activated protein kinases (MAPKs) seems to play a crucial role in the molecular events leading to cytoskeletal disruption.
Export Options
About this article
Cite this article as:
Máthé Csaba, Beyer Dániel, M-Hamvas Márta and Vasas Gábor, The Effects of Microcystins (Cyanobacterial Heptapeptides) on the Eukaryotic Cytoskeletal System, Mini-Reviews in Medicinal Chemistry 2016; 16 (13) . https://dx.doi.org/10.2174/1389557516666160219130732
DOI https://dx.doi.org/10.2174/1389557516666160219130732 |
Print ISSN 1389-5575 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5607 |
Call for Papers in Thematic Issues
Bioprospecting of Natural Products as Sources of New Multitarget Therapies
According to the Convention on Biological Diversity, bioprospecting is the exploration of biodiversity and indigenous knowledge to develop commercially valuable products for pharmaceutical and other applications. Bioprospecting involves searching for useful organic compounds in plants, fungi, marine organisms, and microorganisms. Natural products traditionally constituted the primary source of more than ...read more
Computational Frontiers in Medicinal Chemistry
The thematic issue "Computational Frontiers in Medicinal Chemistry" provides a robust platform for delving into state-of-the-art computational methodologies and technologies that significantly propel advancements in medicinal chemistry. This edition seeks to amalgamate top-tier reviews spotlighting the latest trends and breakthroughs in the fusion of computational approaches, including artificial intelligence (AI) ...read more
Mitochondria as a Therapeutic Target in Metabolic Disorders
Mitochondria are the primary site of adenosine triphosphate (ATP) production in mammalian cells. Moreover, these organelles are an important source of reactive oxygen and nitrogen species in virtually any nucleated cell type. The modulation of a myriad of cellular signaling pathways depends on the mitochondrial physiology. Mitochondrial dysfunction is observed ...read more
Natural Products and Dietary Supplements in Alleviation of Metabolic, Cardiovascular, and Neurological Disorders
Metabolic disorders like diabetes, obesity, inflammation, oxidative stress, cancer etc, cardiovascular disorders like angina, myocardial infarction, congestive heart failure etc as well as neurological disorders like Alzheimer?s, Parkinson?s, Epilepsy, Depression, etc are the global burden. They covered the major segment of the diseases and disorders from which the human community ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Apoptosis Suppression by Candidate Oncogene PLAC8 is Reversed in Other Cell Types
Current Cancer Drug Targets Bamboo a Supplement to Human Health: A Comprehensive Review on its Ethnopharmacology, Phytochemistry, and Pharmacological Activity
The Natural Products Journal Withdrawal Notice: Circulatory Cells as Tumortropic Carrier for Targetability Improvement
Current Drug Delivery Heterocyclic Secretase Inhibitors for the Treatment of Alzheimer’s Disease: An Overview
Central Nervous System Agents in Medicinal Chemistry Cellular Changes, Molecular Pathways and the Immune System Following Photodynamic Treatment
Current Medicinal Chemistry Liposomal-All-trans-Retinoic Acid in the Treatment of Acute Promyelocytic Leukemia
Current Cancer Therapy Reviews Alpha-1-Antichymotrypsin: A Common Player for Type 2 Diabetes and Alzheimer's Disease
Current Diabetes Reviews Fatty Acid-Mediated Inhibition of Metal Binding to the Multi-Metal Site on Serum Albumin: Implications for Cardiovascular Disease
Current Topics in Medicinal Chemistry Topoisomerase I and II Inhibitors: A Patent Review
Recent Patents on Anti-Cancer Drug Discovery Carotenoids as Modulators of Intracellular Signaling Pathways
Current Signal Transduction Therapy Use of Anticancer Platinum Compounds in Combination Therapies and Challenges in Drug Delivery
Current Medicinal Chemistry Immune Checkpoint Regulators: A New Era Toward Promising Cancer Therapy
Current Cancer Drug Targets Recent Developments of DNA Poisons - Human DNA Topoisomerase IIα Inhibitors - as Anticancer Agents
Current Pharmaceutical Design In Vitro Models of Human T Cell Development: Dishing Out Progenitor T Cells
Current Immunology Reviews (Discontinued) Regulation of EMT by KLF4 in Gastrointestinal Cancer
Current Cancer Drug Targets Cancer Stem Cells in Prostate Cancer Chemoresistance
Current Cancer Drug Targets Expanding Targets for a Metabolic Therapy of Cancer: L-Asparaginase
Recent Patents on Anti-Cancer Drug Discovery Patent Selections
Recent Patents on Biomarkers Current and Emerging Therapeutic Approaches in HCV-Related Mixed Cryoglobulinemia
Current Medicinal Chemistry Signaling Mechanism(S) of Reactive Oxygen Species in Epithelial-Mesenchymal Transition Reminiscent of Cancer Stem Cells in Tumor Progression
Current Stem Cell Research & Therapy